The drug developed by U.S. pharmaceutical giant Eli Lilly and Co. will be offered to patients experiencing ... Kisunla will ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

Eli Lilly reported weaker results for the latest quarter than analysts ... In stock markets abroad, indexes were mostly lower ...

Sales have been limited but a recent approval in Japan could make it a significant growth driver in the quarters ahead. Despite falling on Wednesday, Eli Lilly stock is up by about 44% in 2024 as ...

Eli Lilly and Company reported third quarter results ... the approval of Jaypirca in Japan for people with relapsed or refractory mantle cell lymphoma who are resistant or intolerant to other ...

Everyone knows that big pharma companies like Eli Lilly (NYSE: LLY ... in the U.S and regulators in Japan. The U.K.'s regulators concurred with the results of clinical trials suggesting that ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly submitted marketing applications for mirikizumab for Crohn’s disease around the globe, including in the U.S., Canada, Europe, Japan, and China. Additionally, Eli Lilly has a ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

1 Donanemab is approved under the brand name Kisunla™ in the United States, Japan, Great Britain and other countries. These data were presented at Eli Lilly and Company (NYSE: LLY) announced ...

Eli Lilly just got approval in the U.K. to market ... in the U.S and regulators in Japan. The U.K.'s regulators concurred with the results of clinical trials suggesting that the drug is somewhat ...